EGFR and lung carcinoma: For instance, polyethylenimine modified mesoporous SNs were conjugated with EGFR antibody (EGFRAb-SN-pyrrolidine-2) to use as a targeted prodrug delivery for effective lung cancer therapy (Sundarraj et al., 2014).